Description
As one of the most widely-used prescriptions withdrawn from the market, Rofecobix highlights issues facing public health leaders during a drug recall. With approval by the Food and Drug Administration in 1999, Merck marketed the drug for public use. In 2004, the drug was recalled for safety and cardiovascular problems developed in patients taking the medication (Topol, 2004). With nearly $2.5 billion dollars in sales and over 80 million people exposed to the drug, Merck’s recall turned into a public firestorm of litigation cases against the corporation.
In this week’s article by Topol, the author addresses the scandal surrounding safety concerns and the drug recall of Rofecobix. Use the Learning Resources as well as 2–4 additional resources from the Walden Library, current events, etc., to consider the facts in the case. Think about the traits and skills of the primary leaders. After considering the issues in the case, work with your group to address possible shortcomings of primary leadership and systemic issues. Also, as a group, think about strategies for improvements that use a systems thinking approach
Case Study Analysis (3 pages, APA, 5 References)
- The Topol article will be used (link to article listed below). In this paper include the following sections:
- A summary of possible shortcomings of the skills and traits of the primary leaders in the case study
- A description of systemic issues and strategies for system improvement utilizing systems thinking
LINK TO ARTICLE
Explanation & Answer
please find the attached file. i look forward to working with you again. good bye
Running head: CASE STUDY ANALYSIS
1
Case Study Analysis
Student Name
University Affiliation
Instructor
Date of Submission
CASE STUDY ANALYSIS
2
Case Study Analysis
Merck introduced Rofecobix in the market as the best alternative drug to non-Steroidal
and inflammatory medicine so as to treat osteoarthritis pain. Later on, this drug was found to
have risk of cardiovascular diseases and due to this harmful side effects, Rofecobix was
withdrawn from the world market. There are around 300 thousand people who have tabled legal
claim about Merck. Although the company state that it will fight the case filed against it and
deny any liability, there are facts and evidences that support this case. For example, when the
drug was developed, scientist from Merck had suspicion that the drug would have affected the
cardiovascular system. Additionally, in 1996-1997 there was a report which showed that
Rofecobix could reduce urinary metabolite by about a half. Despite this company having
knowledge that the drug might cause effect such as thrombus formation, there were no any
interventions taken by the company to evaluate this risk (Berenson and Haris, 2004).
Leaders play a vital role in the success of any organization or a business enterprise. They
...
Review
Review
